A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Latest Information Update: 04 Jun 2025
At a glance
- Drugs SIBP A17 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Institute of Biological Products
Most Recent Events
- 04 Jun 2025 New trial record
- 03 Jun 2025 Planned initiation date changed from 15 May 2025 to 15 Jun 2025.